Search Results - "Van Nuffel, An MT"
-
1
ReDO_DB: the repurposing drugs in oncology database
Published in Ecancermedicalscience (06-12-2018)“…Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity…”
Get full text
Journal Article -
2
Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent
Published in Ecancermedicalscience (24-02-2015)“…Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections,…”
Get full text
Journal Article -
3
Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
Published in Molecular therapy. Nucleic acids (2013)“…Tumor antigen–encoding mRNA for dendritic cell (DC)-based vaccination has gained increasing popularity in recent years. Within this context, two main…”
Get full text
Journal Article -
4
Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA
Published in Molecular therapy (01-06-2008)“…The effectiveness of the dendritic cell (DC) vaccination protocols that are currently in use could be improved by providing the DCs with a more potent…”
Get full text
Journal Article -
5
Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients
Published in Molecular therapy (01-05-2012)“…It is generally thought that dendritic cells (DCs) loaded with full-length tumor antigen could improve immunotherapy by stimulating broad T-cell responses and…”
Get full text
Journal Article -
6
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70
Published in The Journal of immunology (1950) (15-08-2013)“…Regulatory T cells (Tregs) counteract anticancer immune responses through a number of mechanisms, limiting dendritic cell (DC)-based anticancer immunotherapy…”
Get full text
Journal Article -
7
Characterization of CD8+ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
Published in BioMed research international (01-01-2013)“…Treatment of melanoma patients with mRNA electroporated dendritic cells (TriMixDC-MEL) stimulates T-cell responses against the presented tumor-associated…”
Get full text
Journal Article -
8
Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4 super(+) and CD8 super(+) T Cells in Melanoma Patients
Published in Molecular therapy (01-05-2012)“…It is generally thought that dendritic cells (DCs) loaded with full-length tumor antigen could improve immunotherapy by stimulating broad T-cell responses and…”
Get full text
Journal Article